{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:27:46Z","timestamp":1763695666045,"version":"3.45.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40801-025-00512-y","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:12:37Z","timestamp":1755961957000},"page":"551-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes and Disease Management for Patients with Paroxysmal Nocturnal Haemoglobinuria in China: Results from a Real-World Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-9224","authenticated-orcid":false,"given":"Rong","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Tzu","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Johan","family":"Myr\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Earl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira","family":"Lechat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"7","key":"512_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/17512433.2022.2109462","volume":"15","author":"JW Lee","year":"2022","unstructured":"Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Rev Clin Pharmacol. 2022;15(7):851\u201361. https:\/\/doi.org\/10.1080\/17512433.2022.2109462.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"512_CR2","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28.","journal-title":"Nat Rev Dis Primers"},{"key":"512_CR3","doi-asserted-by":"publisher","first-page":"204062072210910","DOI":"10.1177\/20406207221091046","volume":"13","author":"AG Kulasekararaj","year":"2022","unstructured":"Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022;13:20406207221091050. https:\/\/doi.org\/10.1177\/20406207221091046.","journal-title":"Ther Adv Hematol."},{"issue":"5","key":"512_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Soci\u00e9 G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922\u20139. https:\/\/doi.org\/10.3324\/haematol.2013.093161.","journal-title":"Haematologica"},{"issue":"4","key":"512_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ajh.24278","volume":"91","author":"M Loschi","year":"2016","unstructured":"Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016;91(4):366\u201370. https:\/\/doi.org\/10.1002\/ajh.24278.","journal-title":"Am J Hematol"},{"issue":"23 Suppl 1","key":"512_CR6","doi-asserted-by":"publisher","first-page":"I22","DOI":"10.1161\/01.Cir.0000078464.82671.78","volume":"107","author":"C Kearon","year":"2003","unstructured":"Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I22-30. https:\/\/doi.org\/10.1161\/01.Cir.0000078464.82671.78.","journal-title":"Circulation"},{"issue":"8","key":"512_CR7","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","volume":"112","author":"RP de Latour","year":"2008","unstructured":"de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099\u2013106. https:\/\/doi.org\/10.1182\/blood-2008-01-133918.","journal-title":"Blood"},{"key":"512_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. https:\/\/doi.org\/10.3389\/fimmu.2019.01157.","journal-title":"Front Immunol"},{"issue":"6","key":"512_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","volume":"97","author":"JW Lee","year":"2013","unstructured":"Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean registry. Int J Hematol. 2013;97(6):749\u201357. https:\/\/doi.org\/10.1007\/s12185-013-1346-4.","journal-title":"Int J Hematol"},{"issue":"1","key":"512_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347.","journal-title":"Br J Haematol"},{"issue":"19","key":"512_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253\u20138. https:\/\/doi.org\/10.1056\/NEJM199511093331904.","journal-title":"N Engl J Med"},{"issue":"3","key":"512_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"JI Nishimura","year":"2004","unstructured":"Nishimura JI, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83(3):193\u2013207. https:\/\/doi.org\/10.1097\/01.md.0000126763.68170.46.","journal-title":"Medicine (Baltimore)"},{"issue":"9027","key":"512_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0140-6736(95)12360-1","volume":"348","author":"G Socie","year":"1996","unstructured":"Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French society of haematology. Lancet. 1996;348(9027):573\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(95)12360-1.","journal-title":"Lancet"},{"issue":"25","key":"512_CR14","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786\u201392. https:\/\/doi.org\/10.1182\/blood-2011-02-333997.","journal-title":"Blood"},{"key":"512_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcmd.2017.03.013","volume":"65","author":"MN Yenerel","year":"2017","unstructured":"Yenerel MN, Muus P, Wilson A, Szer J. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. Blood Cells Mol Dis. 2017;65:29\u201334. https:\/\/doi.org\/10.1016\/j.bcmd.2017.03.013.","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"512_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876805.","journal-title":"Blood"},{"issue":"6","key":"512_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876136.","journal-title":"Blood"},{"issue":"2","key":"512_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra2201664","volume":"387","author":"R Notaro","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160\u20136. https:\/\/doi.org\/10.1056\/NEJMra2201664.","journal-title":"N Engl J Med"},{"key":"512_CR19","unstructured":"AstraZeneca. AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China 2022. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/astrazeneca-expands-global-footprint-in-rare-disease-with-availability-of-first-alexion-rare-disease-therapy-for-patients-in-china.html. Accessed: 11-01 2024"},{"issue":"11","key":"512_CR20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"512_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8): e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"512_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380. https:\/\/doi.org\/10.2147\/DMSO.S120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"512_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63\u201374. https:\/\/doi.org\/10.1016\/s0885-3924(96)00274-6.","journal-title":"J Pain Symptom Manage"},{"key":"512_CR24","doi-asserted-by":"publisher","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"10","key":"512_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"4","key":"512_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016.","journal-title":"Value Health"},{"issue":"5","key":"512_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"512_CR28","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct 2020 [updated September 2020]. Available from: https:\/\/www.ephmra.org\/media\/4857\/ephmra-2020-code-of-conduct-final.pdf. Accessed: 21 Jun 2021"},{"key":"512_CR29","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed: 2 Jul 2021"},{"issue":"4","key":"512_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12185-019-02699-7","volume":"110","author":"M Sakurai","year":"2019","unstructured":"Sakurai M, Jang JH, Chou WC, Kim JS, Wilson A, Nishimura JI, et al. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2019;110(4):411\u20138. https:\/\/doi.org\/10.1007\/s12185-019-02699-7.","journal-title":"Int J Hematol"},{"issue":"1","key":"512_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/16078454.2021.2022849","volume":"27","author":"Y Du","year":"2022","unstructured":"Du Y, Yang Y, Yang C, Chen M, Han B. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study. Hematology. 2022;27(1):113\u201321. https:\/\/doi.org\/10.1080\/16078454.2021.2022849.","journal-title":"Hematology"},{"key":"512_CR32","doi-asserted-by":"publisher","first-page":"107602962312130","DOI":"10.1177\/10760296231213073","volume":"30","author":"D Clayton","year":"2024","unstructured":"Clayton D, Shafrin J, Yen G, Lee S, Geevarghese L, Shi Y, et al. Treatment patterns and healthcare resource utilization of patients with paroxysmal nocturnal hemoglobinuria: a retrospective claims data analysis. Clin Appl Thromb Hemost. 2024;30:10760296231213072. https:\/\/doi.org\/10.1177\/10760296231213073.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"18","key":"512_CR33","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311. https:\/\/doi.org\/10.1182\/blood-2014-02-522128.","journal-title":"Blood"},{"issue":"1","key":"512_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/jci114172","volume":"84","author":"MH Holguin","year":"1989","unstructured":"Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84(1):7\u201317. https:\/\/doi.org\/10.1172\/jci114172.","journal-title":"J Clin Invest"},{"issue":"2","key":"512_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3346\/jkms.2016.31.2.214","volume":"31","author":"JH Jang","year":"2016","unstructured":"Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH registry. J Korean Med Sci. 2016;31(2):214\u201321. https:\/\/doi.org\/10.3346\/jkms.2016.31.2.214.","journal-title":"J Korean Med Sci"},{"issue":"1 Suppl 1","key":"512_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminhematol.2008.11.004","volume":"46","author":"NS Young","year":"2009","unstructured":"Young NS, Meyers G, Schrezenmeier H, Hillmen P, Hill A. The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl 1):S1-s16. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.11.004.","journal-title":"Semin Hematol"},{"issue":"6","key":"512_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/ejh.12520","volume":"94","author":"J Schubert","year":"2015","unstructured":"Schubert J, Roth A. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. Eur J Haematol. 2015;94(6):464\u201373. https:\/\/doi.org\/10.1111\/ejh.12520.","journal-title":"Eur J Haematol"},{"issue":"12","key":"512_CR38","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","volume":"106","author":"C Parker","year":"2005","unstructured":"Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699\u2013709. https:\/\/doi.org\/10.1182\/blood-2005-04-1717.","journal-title":"Blood"},{"issue":"4","key":"512_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ejh.13816","volume":"109","author":"J Panse","year":"2022","unstructured":"Panse J, Sicre de Fontbrune F, Burmester P, Piggin M, Matos JE, Costantino H, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. Eur J Haematol. 2022;109(4):351\u201363. https:\/\/doi.org\/10.1111\/ejh.13816.","journal-title":"Eur J Haematol"},{"issue":"11","key":"512_CR40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21(11):1313\u201321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013.","journal-title":"Value Health"},{"issue":"1","key":"512_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41687-023-00609-4","volume":"7","author":"D Cella","year":"2023","unstructured":"Cella D, Johansson P, Ueda Y, Tomazos I, Gustovic P, Wang A, et al. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. J Patient-Report Outcomes. 2023;7(1):63. https:\/\/doi.org\/10.1186\/s41687-023-00609-4.","journal-title":"J Patient-Report Outcomes."},{"issue":"6","key":"512_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M15-0288","volume":"163","author":"WP Battisti","year":"2015","unstructured":"Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461\u20134. https:\/\/doi.org\/10.7326\/M15-0288.","journal-title":"Ann Intern Med"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00512-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00512-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:00Z","timestamp":1763687820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00512-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00512-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"29 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World PNH DSP. Alexion did not influence the original survey through either contribution to the design of questionnaires or data collection. The DSP is a wholly owned Adelphi Real World product. Alexion is one of multiple subscribers to the DSP. Publication of survey results was not contingent on the subscriber\u2019s approval or censorship of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xuefei Liu is a previous employee of AstraZeneca China. All authors declare no competing financial interests related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data, i.e. methodology, materials, data and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Yasmin Taylor at yasmin.taylor@omc.com. Yasmin Taylor is an employee of Adelphi Real World.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Patients provided informed consent to take part in the survey using a checkbox. The PNH DSP was submitted to the Pearl Institutional Review Board (study protocol number no. 21-ADRW-127\/AG9119), and exemption from\u00a0ethical approval was granted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were contributors in writing the manuscript. Rong Fu, Hui Liu, Pin-Tzu Su, Xuefei Liu, Karl-Johan Myr\u00e9n, Francesca Gatta and Elmira Lechat contributed to the study conceptualization and design. Lucy Earl, Yasmin Taylor and Alice Simons contributed to data analysis and interpretation. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}